Cynthia Ma is an Oncology physician. ClinicalTrials.gov lists 15 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
4921 Parkview Pl
Div Im Medical Oncology, Ste 7a, 7b, 7c
Saint Louis, MO 631101032
Telephone
800-647-2098Registry record last updated 17 Apr 2025.
Clinical trials
- Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis
Sponsor: Washington University School of Medicine
- ATI-2231 in Advanced Solid Tumor Malignancies
Sponsor: Washington University School of Medicine
- Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer
Sponsor: National Cancer Institute (NCI)
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
21 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Genentech USA, Inc.Program year20258 payments
- AstraZeneca UK LimitedProgram year20254 payments
- AstraZeneca Pharmaceuticals LPProgram year20255 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
40%PD-1 inhibitor37.6%Pembrolizumab100%Part B, office-administered≥11 patientsAromatase Inhibitor1.4%Letrozole48%Anastrozole34%Exemestane18%Part D≥16 patients+ 3 more classes in this area
Metabolism & gastrointestinal
40%Other antiemetics35.6%Fosaprepitant100%Part B, office-administered≥12 patientsSerotonin-3 Receptor Antagonist4.1%Palonosetron hcl92%Ondansetron Odt5%Ondansetron Hcl3%Part D + Part B<11 patients+ 2 more classes in this area
Musculoskeletal
11.4%RANK Ligand Inhibitor11.4%Denosumab100%Part B, office-administered≥11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
3 NIH research awards on record, funded 2017–2026 per NIH RePORTER. The latest:
- Washington University Co-Clinical Imaging Research Resource
Washington University
FY2026$645,323U24CA209837 - FFNP-PET as a predictive biomarker of response to endocrine therapy approaches in advanced breast cancer
Washington University
FY2025$1,254,028R01CA273194 - Washington University Co-Clinical Imaging Research Resource
Washington University
FY2025$645,323U24CA209837
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”